Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 9, pp 1479–1492 | Cite as

An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation

  • Luciano CastielloEmail author
  • Alessandra Zevini
  • Elisabetta Vulpis
  • Michela Muscolini
  • Matteo Ferrari
  • Enrico Palermo
  • Giovanna Peruzzi
  • Christian Krapp
  • Martin Jakobsen
  • David Olagnier
  • Alessandra Zingoni
  • Angela Santoni
  • John HiscottEmail author
Original Article

Abstract

RIG-I is a cytosolic RNA sensor that recognizes short 5′ triphosphate RNA, commonly generated during virus infection. Upon activation, RIG-I initiates antiviral immunity, and in some circumstances, induces cell death. Because of this dual capacity, RIG-I has emerged as a promising target for cancer immunotherapy. Previously, a sequence-optimized RIG-I agonist (termed M8) was generated and shown to stimulate a robust immune response capable of blocking viral infection and to function as an adjuvant in vaccination strategies. Here, we investigated the potential of M8 as an anti-cancer agent by analyzing its ability to induce cell death and activate the immune response. In multiple cancer cell lines, M8 treatment strongly activated caspase 3-dependent apoptosis, that relied on an intrinsic NOXA and PUMA-driven pathway that was dependent on IFN-I signaling. Additionally, cell death induced by M8 was characterized by the expression of markers of immunogenic cell death-related damage-associated molecular patterns (ICD-DAMP)—calreticulin, HMGB1 and ATP—and high levels of ICD-related cytokines CXCL10, IFNβ, CCL2 and CXCL1. Moreover, M8 increased the levels of HLA-ABC expression on the tumor cell surface, as well as up-regulation of genes involved in antigen processing and presentation. M8 induction of the RIG-I pathway in cancer cells favored dendritic cell phagocytosis and induction of co-stimulatory molecules CD80 and CD86, together with increased expression of IL12 and CXCL10. Altogether, these results highlight the potential of M8 in cancer immunotherapy, with the capacity to induce ICD-DAMP on tumor cells and activate immunostimulatory signals that synergize with current therapies.

Keywords

RIG-I Interferons Cancer immunotherapy Immunogenic cell death Dendritic cells 

Abbreviations

7-AAD

7-Aminoactinomycin D

Ac-YVAD-CMK

Acetyl–tyrosyl-valyl-alanyl-aspartyl–chloromethylketone

APC

Allophycocyanin

APM

Antigen processing machinery

ATCC

American Type Culture Collection

BAX

Bcl-2-associated X protein

BD

Becton Dickinson

BH3

Bcl-2 homology 3

CARD

Caspase recruitment domain

CCCP

Carbonyl cyanide 3-chlorophenylhydrazone

CCL2

C-C motif chemokine ligand 2

CTFR

Cell trace far red

CXCL1

C-X-C motif ligand 1

CXCL10

C-X-C motif chemokine 10

DAMP

Damage-associated molecular patterns

EBV

Epstein–Barr virus

F-12K

Kaighn’s modification of Ham’s F-12 medium

FSC-A

Forward scatter-area

FSC-H

Forward scatter-height

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

Gy

Gray

HEPES

4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid

HLA-ABC

Human leucocyte antigens-A, B, and C loci

HMGB1

High-mobility group box 1

ICD

Immunogenic cell death

IDO1

Indoleamine-pyrrole 2,3-dioxygenase 1

IFNβ

Interferonβ

IFNAR1

Interferon α and β receptor subunit 1

IFN-I

Type-I interferon

IKK

IκB kinase

IRF3

Interferon regulatory factor 3

MAVS

Mitochondrial antiviral signaling protein

MDSC

Myeloid-derived suppressor cells

MiRNA

MicroRNA

MoDC

Monocyte-derived dendritic cells

P/S

Penicillin–streptomycin solution

PAMP

Pathogen-associated molecular patterns

PARP

Poly (ADP-ribose) polymerase

PRR

Pattern recognition receptors

PSMB8/9/10

Proteasome subunit beta type-8, -9, -10

PUMA

p53 upregulated modulator of apoptosis

RA

RIG-I agonist

RIG-I

Retinoic acid-inducible gene-I

RIP1

Receptor-interacting protein 1

RLU

Relative light units

SiRNA

Short interfering RNA

TAM

Tumor-associated macrophages

TAP1/2

Antigen peptide transporter 1, 2

TAPBP

Tapasin

TBK1

TANK-binding kinase 1

VSV

Vesicular stomatitis virus

Z-VAD-FMK

Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone

Notes

Author contributions

Conception and design: LC, AZ, JH, DO. Collection and assembly of data: LC, AZ, EV, MM, MF, EP, GP, CK. Data analysis and interpretation: LC, MJ, DO, AZ, AS, and JH. Manuscript writing: LC, AZ, JH. Final approval of manuscript: all authors.

Funding

This research was supported by grants from Fondazione Cenci Bolognetti, the Italian Association for Cancer Research (AIRC) (IG16901), and NIH Grants 1R561AI108861-01A1 and 7R21CA192185. Elisabetta Vulpis is supported by an AIRC fellowship for Italy.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

PBMC were freshly isolated from peripheral blood samples of anonymous volunteer healthy donors at the Transfusion Center of Sapienza University of Rome. Written informed consent was obtained from all blood donors to the use of their blood for scientific purposes.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Sapienza University of Rome (Rif.3373/250914) and with the 1964 Helsinki declaration. Institutional Review Board approval was not required for this kind of study.

Cell line authentication

Primary Mel1007 and metastatic melanoma Mel120 cells were a kind gift of Dr. G. Parmiani (Milan, Italy), A549, HCT116 and PC3 were all from ATCC. All the experiments were performed with cells at low passage numbers (≤ 10). Cell identity was monitored based on morphology and growth rate. Mycoplasma was routinely tested.

References

  1. 1.
    Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570PubMedCrossRefGoogle Scholar
  2. 2.
    Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol 27:16–25.  https://doi.org/10.1016/j.coi.2014.01.004 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Iurescia S, Fioretti D, Rinaldi M (2018) Targeting cytosolic nucleic acid-sensing pathways for cancer immunotherapies. Front Immunol 9:711.  https://doi.org/10.3389/fimmu.2018.00711 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hornung V, Ellegast J, Kim S et al (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314:994–997.  https://doi.org/10.1126/science.1132505 CrossRefPubMedGoogle Scholar
  5. 5.
    Kawai T, Takahashi K, Sato S et al (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6:981–988.  https://doi.org/10.1038/ni1243 CrossRefPubMedGoogle Scholar
  6. 6.
    Goulet M-LL, Olagnier D, Xu Z et al (2013) Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 9:e1003298.  https://doi.org/10.1371/journal.ppat.1003298 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zevini A, Olagnier D, Hiscott J (2017) Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol 38:194–205CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Heylbroeck C, Balachandran S, Servant MJ et al (2000) The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 74:3781–3792.  https://doi.org/10.1128/JVI.74.8.3781-3792.2000 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chattopadhyay S, Kuzmanovic T, Zhang Y et al (2016) Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral pathogenesis. Immunity 44:1151–1161.  https://doi.org/10.1016/j.immuni.2016.04.009 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schock SN, Chandra NV, Sun Y et al (2017) Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway. Cell Death Differ 24:615–625.  https://doi.org/10.1038/cdd.2016.153 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Poeck H, Besch R, Maihoefer C et al (2008) 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14:1256–1263.  https://doi.org/10.1038/nm.1887 CrossRefPubMedGoogle Scholar
  12. 12.
    Besch R, Poeck H, Hohenauer T et al (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells. J Clin Investig 119:2399–2411.  https://doi.org/10.1172/JCI37155 CrossRefPubMedGoogle Scholar
  13. 13.
    Glas M, Coch C, Trageser D et al (2013) Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells 31:1064–1074.  https://doi.org/10.1002/stem.1350 CrossRefPubMedGoogle Scholar
  14. 14.
    Ellermeier J, Wei J, Duewell P et al (2013) Therapeutic efficacy of bifunctional siRNA combining TGF-1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 73:1709–1720.  https://doi.org/10.1158/0008-5472.CAN-11-3850 CrossRefPubMedGoogle Scholar
  15. 15.
    Duewell P, Steger A, Lohr H et al (2014) RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death Differ 21:1825–1837.  https://doi.org/10.1038/cdd.2014.96 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chiang C, Beljanski V, Yin K et al (2015) Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol 89:8011–8025.  https://doi.org/10.1128/JVI.00845-15 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Beljanski V, Chiang C, Kirchenbaum GA et al (2015) Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J Virol 89:10612–10624.  https://doi.org/10.1128/JVI.01526-15 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zingoni A, Palmieri G, Morrone S et al (2000) CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur J Immunol 30:644–651.  https://doi.org/10.1002/1521-4141(200002)30:2%3c644:AID-IMMU644%3e3.0.CO;2-H CrossRefPubMedGoogle Scholar
  19. 19.
    Galluzzi L, Buqué A, Kepp O et al (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17:97–111.  https://doi.org/10.1038/nri.2016.107 CrossRefPubMedGoogle Scholar
  20. 20.
    Leone P, Shin E-C, Perosa F et al (2013) MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. JNCI J Natl Cancer Inst 105:1172–1187.  https://doi.org/10.1093/jnci/djt184 CrossRefPubMedGoogle Scholar
  21. 21.
    Dunn GP, Bruce AT, Sheehan KCF et al (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6:722–729.  https://doi.org/10.1038/ni1213 CrossRefPubMedGoogle Scholar
  22. 22.
    Katlinskaya YV, Katlinski KV, Yu Q et al (2016) Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep 15:171–180.  https://doi.org/10.1016/J.CELREP.2016.03.006 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Katlinski KV, Gui J, Katlinskaya YV et al (2017) Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31:194–207.  https://doi.org/10.1016/j.ccell.2017.01.004 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Castiello L, Sestili P, Schiavoni G et al (2018) Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells. Cancer Immunol Res 6:658–670.  https://doi.org/10.1158/2326-6066.CIR-17-0675 CrossRefPubMedGoogle Scholar
  25. 25.
    Rizza P, Moretti F, Capone I, Belardelli F (2015) Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev 26:195–201.  https://doi.org/10.1016/j.cytogfr.2014.10.002 CrossRefPubMedGoogle Scholar
  26. 26.
    Gajewski TF, Fuertes MB, Woo S-R (2012) Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother 61:1343–1347.  https://doi.org/10.1007/s00262-012-1305-6 CrossRefPubMedGoogle Scholar
  27. 27.
    Snell LM, Mcgaha TL, Brooks DG (2017) Type I interferon in chronic virus infection and cancer. Trends Immunol 38:542–557.  https://doi.org/10.1016/j.it.2017.05.005 CrossRefPubMedGoogle Scholar
  28. 28.
    HuangFu W-C, Qian J, Liu C et al (2012) Inflammatory signaling compromises cell responses to interferon alpha. Oncogene 31:161–172.  https://doi.org/10.1038/onc.2011.221 CrossRefPubMedGoogle Scholar
  29. 29.
    Bhattacharya S, HuangFu W-C, Dong G et al (2013) Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 32:4214–4221.  https://doi.org/10.1038/onc.2012.439 CrossRefPubMedGoogle Scholar
  30. 30.
    Levin D, Harari D, Schreiber G (2011) Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol 31:3252–3266.  https://doi.org/10.1128/MCB.05251-11 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Stojdl DF, Lichty BD, tenOever BR et al (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263–275CrossRefPubMedGoogle Scholar
  32. 32.
    Nguyen TL-A, Abdelbary H, Arguello M et al (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci 105:14981–14986.  https://doi.org/10.1073/pnas.0803988105 CrossRefPubMedGoogle Scholar
  33. 33.
    Olagnier D, Lababidi RR, Hadj SB et al (2017) Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity. Mol Ther 25:1900–1916.  https://doi.org/10.1016/j.ymthe.2017.04.022 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sanchez-Correa B, Morgado S, Gayoso I et al (2011) Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 60:1195–1205.  https://doi.org/10.1007/s00262-011-1050-2 CrossRefPubMedGoogle Scholar
  35. 35.
    Zingoni A, Fionda C, Borrelli C et al (2017) Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol 8:1194.  https://doi.org/10.3389/fimmu.2017.01194 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Barsoum J, Renn M, Schuberth C, et al (2017) Abstract B44: Selective stimulation of RIG-I with a novel synthetic RNA induces strong anti-tumor immunity in mouse tumor models. In: Cancer Immunology Research. American Association for Cancer Research, pp B44–B44Google Scholar
  37. 37.
    Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Rizvi NA, Hellmann MD, Snyder A et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128.  https://doi.org/10.1126/science.aaa1348 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207–211.  https://doi.org/10.1126/science.aad0095 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zong J, Keskinov AA, Shurin GV, Shurin MR (2016) Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother 65:821–833.  https://doi.org/10.1007/s00262-016-1820-y CrossRefPubMedGoogle Scholar
  41. 41.
    Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74.  https://doi.org/10.1126/science.aaa4971 CrossRefPubMedGoogle Scholar
  42. 42.
    Elion DL, Jacobson ME, Hicks DJ et al (2018) Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res.  https://doi.org/10.1158/0008-5472.CAN-18-0730 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Luciano Castiello
    • 1
    • 5
    Email author
  • Alessandra Zevini
    • 1
  • Elisabetta Vulpis
    • 2
  • Michela Muscolini
    • 1
  • Matteo Ferrari
    • 1
  • Enrico Palermo
    • 1
  • Giovanna Peruzzi
    • 3
  • Christian Krapp
    • 4
  • Martin Jakobsen
    • 4
  • David Olagnier
    • 4
  • Alessandra Zingoni
    • 2
  • Angela Santoni
    • 1
    • 2
  • John Hiscott
    • 1
    Email author
  1. 1.Istituto Pasteur Italia-Cenci Bolognetti FoundationRomeItaly
  2. 2.Department of Molecular MedicineSapienza UniversityRomeItaly
  3. 3.Center for Life Nano Science@SapienzaIstituto Italiano di TecnologiaRomeItaly
  4. 4.Department of BiomedicineAarhus UniversityAarhusDenmark
  5. 5.FaBioCell, Core FacilitiesIstituto Superiore di SanitàRomeItaly

Personalised recommendations